[go: up one dir, main page]

NO20072548L - Xanthine derivatives with HM74A receptor activity - Google Patents

Xanthine derivatives with HM74A receptor activity

Info

Publication number
NO20072548L
NO20072548L NO20072548A NO20072548A NO20072548L NO 20072548 L NO20072548 L NO 20072548L NO 20072548 A NO20072548 A NO 20072548A NO 20072548 A NO20072548 A NO 20072548A NO 20072548 L NO20072548 L NO 20072548L
Authority
NO
Norway
Prior art keywords
xanthine derivatives
receptor activity
hm74a receptor
derivatives
activation
Prior art date
Application number
NO20072548A
Other languages
Norwegian (no)
Inventor
Ivan Leo Pinto
Richard Jonathan Daniel Hatley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0423568A external-priority patent/GB0423568D0/en
Priority claimed from GB0427079A external-priority patent/GB0427079D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20072548L publication Critical patent/NO20072548L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Foreliggende oppfinnelse angår terapeutisk aktive forbindelser med formel (I) som er xantinderivater, fremgangsmåter for fremstilling av nevnte derivater, farmasøytiske formuleringer som inneholder de aktive forbindelsene og anvendelse av forbindelsene ved behandling, særlig ved behandling av sykdommer hvor under-aktivering av HM74A reseptoren bidrar til sykdommen eller hvor aktivering av reseptoren vil være fordelaktig.The present invention relates to therapeutically active compounds of formula (I) which are xanthine derivatives, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compounds and the use of the compounds in treatment, especially in the treatment of diseases in which under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial.

NO20072548A 2004-10-22 2007-05-18 Xanthine derivatives with HM74A receptor activity NO20072548L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0423568A GB0423568D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0427079A GB0427079D0 (en) 2004-12-10 2004-12-10 Novel compounds
PCT/EP2005/011376 WO2006045565A1 (en) 2004-10-22 2005-10-20 Xanthine derivatives with hm74a receptor activity

Publications (1)

Publication Number Publication Date
NO20072548L true NO20072548L (en) 2007-07-20

Family

ID=35601705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072548A NO20072548L (en) 2004-10-22 2007-05-18 Xanthine derivatives with HM74A receptor activity

Country Status (12)

Country Link
EP (1) EP1805180A1 (en)
JP (1) JP2008517029A (en)
KR (1) KR20070070231A (en)
AU (1) AU2005298891A1 (en)
BR (1) BRPI0517458A (en)
CA (1) CA2584904A1 (en)
IL (1) IL182586A0 (en)
MA (1) MA28940B1 (en)
MX (1) MX2007004882A (en)
NO (1) NO20072548L (en)
RU (1) RU2007118932A (en)
WO (1) WO2006045565A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1885726B1 (en) 2005-05-17 2016-12-14 Merck Sharp & Dohme Corp. Ortho-condensed 2-pyridinone derivatives as nicotinic acid receptor agonists for the treatment of dyslipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
SI1901731T1 (en) 2005-06-28 2011-07-29 Merck Sharp & Dohme Niacin receptor agonists, compositions containing such compounds and methods of treatment
JP2009504592A (en) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション Xanthine derivatives as selective HM74A agonists
EP1947092B1 (en) * 2005-11-09 2015-04-15 Tosoh Corporation Method for producing nucleic acid base having perfluoroalkyl group
JP5053622B2 (en) * 2005-11-09 2012-10-17 東ソー株式会社 Nucleobase having a perfluoroalkyl group and method for producing the same
AU2007208478A1 (en) 2006-01-20 2007-08-02 Schering Corpooration Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
CN101466714B (en) 2006-06-23 2013-02-06 英赛特股份有限公司 Purinone derivatives as HM74A agonists
AU2007260852B2 (en) 2006-06-23 2013-01-10 Incyte Corporation Purinone derivatives as HM74a agonists
EP2061767B1 (en) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Novel crystalline diphenylazetidinone hydrates and process for their preparation
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CN102482312A (en) 2009-08-26 2012-05-30 赛诺菲 Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (en) 2011-03-08 2015-04-22 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (en) 2011-03-08 2015-06-24 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2879271A (en) * 1953-07-23 1959-03-24 Knoll Ag Basic derivatives of mono- and dimethyl xanthines, and a process of making same
FR2531085A1 (en) * 1982-07-28 1984-02-03 Adir NOVEL XANTHINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
WO2002084298A2 (en) * 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity

Also Published As

Publication number Publication date
BRPI0517458A (en) 2008-10-07
WO2006045565A1 (en) 2006-05-04
AU2005298891A1 (en) 2006-05-04
RU2007118932A (en) 2008-11-27
CA2584904A1 (en) 2006-05-04
JP2008517029A (en) 2008-05-22
MX2007004882A (en) 2007-05-09
IL182586A0 (en) 2007-07-24
KR20070070231A (en) 2007-07-03
EP1805180A1 (en) 2007-07-11
MA28940B1 (en) 2007-10-01

Similar Documents

Publication Publication Date Title
NO20072548L (en) Xanthine derivatives with HM74A receptor activity
NO20081212L (en) Xanthine derivatives as selective HM74A agonists
HRP20130406T1 (en) Medicaments with hm74a receptor activity
NO20071246L (en) Quinazolinone derivatives and their use as B-RAF inhibitors.
NO20072784L (en) Pyridene carboxamide derivatives for use as anticancer agents
NO20073719L (en) Chemical connections
NO20071776L (en) Kinoxalines as B RAF inhibitors.
NO20070487L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
NO20070199L (en) Substituted quinazolones as anti-cancer agents
NO20082709L (en) Chemical connections
NO20070566L (en) Azine carboxamides as an anticancer agent
EA017278B9 (en) Azaindazole compounds and methods of use
NO20082643L (en) Isoquinolinaminopyrazole derivatives, their preparation and use as pharmaceutical agents for the treatment of cancer
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
UA103272C2 (en) 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS$ 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR INHIBITORS OR BACE2
TW200606162A (en) Pyrazolopyridine derivatives
NO20064584L (en) Tetrahydropyridoindolderivater
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20090266L (en) Piperazinyl derivatives useful in the treatment of GPR38 receptor-mediated diseases
TW200611695A (en) Pyrrolopyridine derivatives
TW200621259A (en) Chemical compounds
WO2006085113A3 (en) 2-substituted 5-membered heteroaryl carboxylates as hm74a receptor agonists
NO20070061L (en) 3-beta-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application